We have located links that may give you full text access.
Carbon monoxide poisoning in racing car drivers.
BACKGROUND: To determine if carbon monoxide (CO) exposure during competition racing is significant enough to cause post-racing symptoms among professional racing drivers.
METHODS: Closed vehicle professional racing drivers were questioned after competition regarding symptoms consistent with heat exposure, dehydration, and carbon monoxide poisoning. All drivers, regardless of symptoms, underwent expired CO monitoring using a breath analyzer both before and after competition events. CO measurements were performed prior to any post-race interviews. Driver smoking history, laps at low speed (under caution), cockpit fire or damage to the exhaust system were also noted. An association between driver symptoms, track and vehicle condition, and increases in expired CO levels during racing was sought.
RESULTS: Twenty-eight drivers completed the study. Each driver was tested both before and after each competition event, and some drivers were tested at different tracks. All of the tested drivers experienced an increase in carboxyhemoglobin concentrations during the competition event. Drivers who smoked had higher baseline levels than non-smokers, but were no more likely to have symptoms. The driver with the highest post-race CO level was exposed to a fire which completely destroyed the vehicle, but he complained of no symptoms after the race. Most drivers complained of post-race symptoms or appeared symptomatic, but no correlation could be shown between post-race CO levels and symptoms.
CONCLUSIONS: There is a mild increase in driver CO levels during professional road racing competition, however, no correlation with CO level and driver symptomatology can be demonstrated. Carbon monoxide does not appear to be a significant cause of post-race driver symptoms such as fatigue, nausea, headache, and weakness.
METHODS: Closed vehicle professional racing drivers were questioned after competition regarding symptoms consistent with heat exposure, dehydration, and carbon monoxide poisoning. All drivers, regardless of symptoms, underwent expired CO monitoring using a breath analyzer both before and after competition events. CO measurements were performed prior to any post-race interviews. Driver smoking history, laps at low speed (under caution), cockpit fire or damage to the exhaust system were also noted. An association between driver symptoms, track and vehicle condition, and increases in expired CO levels during racing was sought.
RESULTS: Twenty-eight drivers completed the study. Each driver was tested both before and after each competition event, and some drivers were tested at different tracks. All of the tested drivers experienced an increase in carboxyhemoglobin concentrations during the competition event. Drivers who smoked had higher baseline levels than non-smokers, but were no more likely to have symptoms. The driver with the highest post-race CO level was exposed to a fire which completely destroyed the vehicle, but he complained of no symptoms after the race. Most drivers complained of post-race symptoms or appeared symptomatic, but no correlation could be shown between post-race CO levels and symptoms.
CONCLUSIONS: There is a mild increase in driver CO levels during professional road racing competition, however, no correlation with CO level and driver symptomatology can be demonstrated. Carbon monoxide does not appear to be a significant cause of post-race driver symptoms such as fatigue, nausea, headache, and weakness.
Full text links
Related Resources
Trending Papers
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Anti-Arrhythmic Effects of Heart Failure Guideline-Directed Medical Therapy and Their Role in the Prevention of Sudden Cardiac Death: From Beta-Blockers to Sodium-Glucose Cotransporter 2 Inhibitors and Beyond.Journal of Clinical Medicine 2024 Februrary 27
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app